82386 Federal Register / Vol. 88, No. 225 / Friday, November 24, 2023 / Notices 

The Agency received requests for 

extension of the comment period for the 

revised draft guidance. After 

considering the requests, and in light of 

the fact that the original comment 

period is scheduled to close on 

December 26, 2023, FDA has decided to 

extend the comment period for the 

revised draft guidance until January 5, 

2024. The Agency believes that this 

extension allows adequate time for 

interested persons to submit comments 

to ensure that FDA can consider the 

comments before it begins work on the 

final version of the guidance. 

Dated: November 20, 2023. 

Lauren K. Roth, 

Associate Commissioner for Policy. 

[FR Doc. 2023–25969 Filed 11–22–23; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Meeting of the Presidential Advisory 

Council on HIV/AIDS 

AGENCY: Office of the Assistant 

Secretary for Health, Office of the 

Secretary, Department of Health and 

Human Services. 

ACTION: Notice of a virtual meeting. 

SUMMARY: As stipulated by the Federal 

Advisory Committee Act, the U.S. 

Department of Health and Human 

Service is hereby giving notice that the 

Presidential Advisory Council on HIV/ 

AIDS (PACHA or the Council) will 

convene the 79th full council meeting 

utilizing virtual technologies on 

Wednesday, December 6, 2023. The 

meeting will be open to the public and 

there will be a public comment session 

during the meeting; pre-registration is 

required to provide public comment. To 

pre-register to provide public comment, 

please send an email to PACHA@

hhs.gov and include your name, 

organization, and title by close of 

business Monday, November 27, 2023. If 

you decide you would like to provide 

public comment but do not pre-register, 

you may submit your written statement 

by emailing PACHA@hhs.gov by close of 

business Wednesday, December 13, 

2023. The meeting agenda will be 

posted on the PACHA page on HIV.gov 

at https://www.hiv.gov/federalresponse/pacha/about-pacha prior to 

the meeting. 

DATES: The meeting will be held on 

Wednesday, December 6 from 

approximately 11:00 a.m.–06:00 p.m. 

(ET). 

ADDRESSES: To attend the meeting 

virtually, please visit www.hhs.gov/live. 

FOR FURTHER INFORMATION CONTACT: Ms. 

Caroline Talev, MPA, Senior 

Management Analyst, at PACHA@

hhs.gov or Caroline.Talev@hhs.gov or 

(202) 795–7622. Additional information 

can be obtained by accessing the 

Council’s page on the HIV.gov site at 

www.hiv.gov/pacha. 

SUPPLEMENTARY INFORMATION: PACHA 

was established by Executive Order 

12963, dated June 14, 1995, as amended 

by Executive Order 13009, dated June 

14, 1996 and is currently operating 

under the authority given in Executive 

Order 14048, dated September 30, 2021. 

The Council was established to provide 

advice, information, and 

recommendations to the Secretary 

regarding programs and policies 

intended to promote effective HIV 

diagnosis, treatment, prevention, and 

quality care services. The functions of 

the Council are solely advisory in 

nature. The Council consists of not more 

than 35 members. Council members are 

selected from prominent community 

leaders with particular expertise in, or 

knowledge of, matters concerning HIV 

and AIDS, public health, global health, 

population health, philanthropy, 

marketing or business, as well as other 

national leaders held in high esteem 

from other sectors of society. PACHA 

selections also include persons with 

lived HIV experience and racial/ethnic 

and sexual and gender minority persons 

disproportionately affected by HIV. 

Council members are appointed by the 

Secretary. 

Dated: October 31, 2023. 

B. Kaye Hayes, 

Deputy Assistant Secretary for Infectious 

Disease, Director, Office of Infectious Disease 

and HIV/AIDS Policy, Executive Director, 

Presidential Advisory Council on HIV/AIDS, 

Office of the Assistant Secretary for Health, 

Department of Health and Human Services. 

[FR Doc. 2023–25877 Filed 11–22–23; 8:45 am] 

BILLING CODE 4150–43–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Center for Advancing 

Translational Sciences; Amended 

Notice of Meeting 

Notice is hereby given of a change in 

the meeting of the National Center for 

Advancing Translational Sciences 

Special Emphasis Panel, Preclinical 

Proof of Concept Studies for Rare 

Diseases (R21) January 24, 2024, 9:00 

a.m. to January 25, 2024, 5:00 p.m., 

National Institutes of Health, National 

Center for Advancing Translational 

Sciences, 6701 Democracy Boulevard, 

Bethesda, MD, 20892 which was 

published in the Federal Register on 

November 14, 2023, FR DOC 2023– 

25070, 88 FR 78052. 

The meeting is being rescheduled due 

to panel member availability. The 

meeting will be held on February 1, 

2024, 9:00 a.m. to February 2, 2024, 5:00 

p.m. This meeting will be held virtually. 

The meeting is closed to the public. 

Dated: November 17, 2023. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2023–25885 Filed 11–22–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; NIAID Investigator Initiated 

Program Project Applications (P01 Clinical 

Trial Not Allowed). 

Date: December 20, 2023. 

Time: 12:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 903 South 4th Street, RML 31/3118, 

Hamilton, MT 59840 (Virtual Meeting). 

Contact Person: Kristin L. McNally, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

National Institute of Allergy and Infectious 

Diseases, National Institutes of Health, 903 

South 4th Street, RML 31/3118, Hamilton, 

MT 59840 mcnallyk@niaid.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 


ddrumheller on DSK120RN23PROD with NOTICES1